Welcome to our dedicated page for Constellium Se SEC filings (Ticker: CSTM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Constellium SE filings document the reporting framework for a France-incorporated aluminum products manufacturer whose ordinary shares trade on the New York Stock Exchange under CSTM. Form 8-K reports furnish quarterly and annual operating results, investor presentations, exhibits and other material-event disclosures tied to segment performance, cash flow, leverage and capital allocation.
Proxy materials cover annual meeting matters, shareholder voting, board governance and executive compensation disclosures, including pay-versus-performance data. The filing record also documents capital-structure and governance matters such as ordinary-share registration information and board-authorized share repurchase actions.
Jurkovic Philip Ryan reported acquisition or exercise transactions in this Form 4 filing.
Constellium SE senior vice president and CHRO Philip Ryan Jurkovic received a grant of 10,210 restricted stock units representing ordinary shares as executive compensation. The award was reported at a price of zero per share and increases his direct holdings to 220,933 ordinary shares.
The restricted stock units vest in full on March 12, 2029, subject to his continued employment, meaning he must remain with the company until that date to receive the underlying shares.
CONSTELLIUM SE senior vice president Ludovic Piquier reported an acquisition of 5,469 ordinary shares through a grant of restricted stock units. The units were granted at no cash cost and will vest in full on March 12, 2029, conditioned on his continued employment.
Following this equity award, Piquier directly holds 242,713 ordinary shares. This filing reflects a compensation-related stock grant rather than an open-market purchase or sale, increasing his long-term ownership stake in the company.
Becker Marcus reported acquisition or exercise transactions in this Form 4 filing.
Constellium SE reported that senior vice president and chief procurement officer Marcus Becker received a grant of 3,938 restricted stock units representing ordinary shares. These units were awarded at no cash cost and vest in full on March 12, 2029, subject to his continued employment. Following this compensation-related award, Becker directly owns 37,175 ordinary shares.
Joerg Ingrid reported acquisition or exercise transactions in this Form 4 filing.
CONSTELLIUM SE CEO Ingrid Joerg received a compensation-related equity grant. On March 12, 2026, she was awarded 31,358 ordinary shares in the form of restricted stock units, which vest in full on March 12, 2029, subject to continued employment. After this grant, she directly holds 409,448 shares.
Perkins Matthew B. reported acquisition or exercise transactions in this Form 4 filing.
CONSTELLIUM SE reported that executive Matthew B. Perkins, President, P&ARP, received an equity award in the form of 10,210 ordinary shares on March 12, 2026. The award was recorded at a price of $0.00 per share, indicating it is a compensation grant rather than an open-market purchase.
According to the footnote, this represents a grant of restricted stock units that vest in full on March 12, 2029, provided he remains employed through that date. Following this grant, Perkins directly holds 33,212 ordinary shares, reflecting his ongoing equity-based alignment with the company.
Schild Niklaus reported acquisition or exercise transactions in this Form 4 filing.
Constellium SE senior vice president and chief information and digital officer Niklaus Schild reported an equity compensation award. He received 3,355 restricted stock units tied to Constellium ordinary shares, granted at no purchase price. These units vest in full on March 12, 2029, subject to his continued employment.
Following this grant, Schild directly holds 38,703 ordinary shares of Constellium. The transaction reflects routine stock-based compensation rather than an open-market share purchase or sale.
Hoffmann Philippe reported acquisition or exercise transactions in this Form 4 filing.
CONSTELLIUM SE reported that President, A&T Philippe Hoffmann received an equity award in the form of restricted stock units. On March 12, 2026, he was granted 12,033 ordinary shares at a price of $0.00 per share as compensation. Following this grant, his direct holdings increased to 194,153 ordinary shares. According to the disclosure, these restricted stock units vest in full on March 12, 2029, provided he remains employed with the company through that date.
Corre Stephane reported acquisition or exercise transactions in this Form 4 filing.
Constellium SE reported that executive Stephane Corre, President of Automotive Structures & Industry, received a grant of 7,293 ordinary shares in the form of restricted stock units at no cash cost. These units vest in full on March 12, 2029, contingent on his continued employment. Following this equity award, Corre directly holds 72,313 ordinary shares of Constellium, aligning a portion of his compensation with the company’s long-term share performance.
Guo Jack Q. reported acquisition or exercise transactions in this Form 4 filing.
Constellium SE EVP & CFO Jack Q. Guo received a grant of 19,690 ordinary shares in the form of restricted stock units, with no purchase price.
Following this award, he directly holds 210,569 ordinary shares. The RSUs vest in full on March 12, 2029, subject to continued employment.
Constellium SE announced that its Board of Directors has authorized a new share repurchase program of up to $300 million of outstanding ordinary shares. The program will become effective after the 2026 Annual General Meeting on May 21, 2026 and run through December 31, 2028, replacing the program approved in February 2024.
The company may buy back shares for cash in open-market or privately negotiated transactions and can use Rule 10b5-1 plans, in line with U.S. securities rules and French corporate law. The Board is not required to repurchase any specific amount and may modify, suspend, extend, or terminate the program at any time. Management highlights this authorization as part of a balanced capital allocation strategy to return capital to shareholders. Constellium reports $8.4 billion of revenue in 2025.